Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer

INTRODUCTION: Tyrosine kinase inhibitors (TKIs) have significantly improved the progression-free survival (PFS) of metastatic non-small cell lung cancer (NSCLC) with oncogene mutations of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) compared with systemic therapy alon...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMJ Open
Autori principali: Tibdewal, Anil, Agarwal, JaiPrakash, Mummudi, Naveen, Noronha, Vanita, Prabhash, Kumar, Patil, Vijay, Purandare, Nilendu, Janu, Amit, Kaushal, Rajiv, Kannan, Sadhna
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2021
Soggetti:
Oncology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7887350/
https://ncbi.nlm.nih.gov/pubmed/33589450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-041345
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi